Botulinum toxin for meralgia paresthetica in type 2 diabetes

Pawan Dhull; A K Tewari; Vimal Upreti; M S Prakash; K V S Hari Kumar

doi:10.1016/j.dsx.2013.02.028

Botulinum toxin for meralgia paresthetica in type 2 diabetes

Diabetes Metab Syndr. 2013 Jan-Mar;7(1):1-2. doi: 10.1016/j.dsx.2013.02.028. Epub 2013 Mar 9.

Authors

Pawan Dhull¹, A K Tewari, Vimal Upreti, M S Prakash, K V S Hari Kumar

Affiliation

¹ Department of Neurology, Command Hospital, Bangalore, India.

PMID: 23517786
DOI: 10.1016/j.dsx.2013.02.028

Abstract

Botulinum toxin has been used for a variety of neuropathic conditions in diabetes mellitus. Meralgia paresthetica is a mononeuropathy of femoral nerve seen in diabetes and obesity with an unclear etiopathogenesis. We studied the role of botulinum toxin in resistant cases of meralgia paresthetica in type 2 diabetes.

Publication types

Clinical Trial

MeSH terms

Adult
Anti-Dyskinesia Agents / administration & dosage
Anti-Dyskinesia Agents / adverse effects
Anti-Dyskinesia Agents / therapeutic use*
Botulinum Toxins / administration & dosage
Botulinum Toxins / adverse effects
Botulinum Toxins / therapeutic use*
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / physiopathology
Female
Femoral Neuropathy
Glycated Hemoglobin
Humans
Injections, Intradermal
Male
Middle Aged
Nerve Compression Syndromes / drug therapy*
Nerve Compression Syndromes / etiology
Nerve Compression Syndromes / physiopathology
Neural Conduction / drug effects*
Obesity / complications
Pilot Projects
Receptors, Calcitonin Gene-Related Peptide / drug effects
Receptors, Glutamate / drug effects
Receptors, Neurokinin-1 / drug effects
Thigh / innervation*
Treatment Outcome

Substances

Anti-Dyskinesia Agents
Glycated Hemoglobin A
Receptors, Calcitonin Gene-Related Peptide
Receptors, Glutamate
Receptors, Neurokinin-1
hemoglobin A1c protein, human
Botulinum Toxins